**Evidence Table 6. Benefits (KQ1 & 2)**

|  |  |  |
| --- | --- | --- |
| Author, Year, Trial Name  | Prevention or Reduction in Physical Health Conditions or Symptoms  | Reduction in Risk-Taking Behaviors, Behavioral Problems, or Criminal Activities |
| Ahrens, 20021NA | NR | NR |
| Berger, 20072OTT | DPS (range: 0-6), MeanG1: 2.1 (SD=1.7)G2: 1.9 (SD=1.6)Within group change at post-treatment:G1: -1.0 (calculated)G2: 0.1 (calculated)Between group change at post-treatment: -1.1 (calculated)Between group ANOVA: F=40.44, df=1,140, p<0.001 | NR |
| Berger, 20093ES-SL | DPS (range: 0-5), MeanPretreatment G1: 1.46 (SD=1.0)G2: 1.26 (SD=1.0)Within group change at post-treatment:G1: -0.82 (calculated)G2: 0.19 (calculated)Between group change at post-treatment: -1.01 (calculated)Between group ANOVA: F=44.80, df=1,164, p<0.001 | NR |
| Berkowitz, 20114NA | NR | NR |
| Catani, 20095NA | # of physical symptomsPretreatment G1: 1.75 (SD=1.34)G2: 1.80 (SD=1.26)Within group change at post-treatment assessment: G1: -0.25 (calculated)G2: -1.13 (calculated)Within group change at 6 Mos.: G1: -0.25 (calculated)G2: -0.51 (calculated)Between group change at post-treatment assessment:0.88 (calculated) Repeated measures ANOVA for time\*treatment interaction p=NSBetween group change at 6 Mos. assessment: 0.26 (calculated)Repeated measures ANOVA for time\*treatment interaction p=NS | NR |

Evidence Table 6. Benefits (KQ1 & 2) (continued)

|  |  |  |
| --- | --- | --- |
| Author, Year, Trial Name  | Prevention or Reduction in Physical Health Conditions or Symptoms  | Reduction in Risk-Taking Behaviors, Behavioral Problems, or Criminal Activities |
| Ford, 20126TARGET | NR | NR  |
| Gelkopf, 20097ERASE-Stress | DPS (range 0-5), MeanPretreatment G1: 2.1 (SD=1.3)G2: 1.9 (SD=1.2)Within group change at post-treatment:G1: -1.0 (calculated)G2: unknown based on data reporting errorBetween group change at post-treatment: unknown based on data reporting errorBetween group ANOVA: F=24.07, df=1,106, p<0.001 | NR |
| Goenjian, 1997; 20058, 9NA; NA | NR | NR |
| Jaycox, 200910SSET | NR | NR |
| Kemp, 201011NA | GHQ-12-General Health (range: 0-12)Pretreatment G1: 1.09 (SD=1.92)G2: 4.25 (SD=4.11)Within group change:G1: 0.82 (calculated)G2: -0.42 (calculated)Between group change: 1.24 (calculated) p=NS  | CBCL, Parent rating (range: 30-100), Pretreatment G1: 36.73 (SD=22.49)G2: 30.10 (SD=34.16)Within group change:G1: -8.28 (calculated)G2: 13.07 (calculated)Between group change (95% CI): -21.35 (calculated) p=NS |
| Layne, 200812TGCT  | NR | NR |
| Nugent, 201013NA | No between group difference in heart rate during or after trauma narrative p=NSNo other data given | NR |
| Robbd, 201014NA | NR | NR |
| Roberte, 199915NA | NR | NR |
| Robertf, 200816NA | NR | NR |

Evidence Table 6. Benefits (KQ1 & 2) (continued)

|  |  |  |
| --- | --- | --- |
| Author, Year, Trial Name  | Prevention or Reduction in Physical Health Conditions or Symptoms  | Reduction in Risk-Taking Behaviors, Behavioral Problems, or Criminal Activities |
| Salloumg, 200817NA | NR | NR |
| Salloum, 201218 NA | NA | CBCL (range: NR), t-score of 63+ (clinically significant parent-reported internalizing problem behavior)Pretreatment:G1: 20.5%G2: 12.1%Within group change at 12 Mos. assessment:G1: -14.6%G2: 1.2%Between group change at 12 Mos. assessment: 15.8%, p=NRCBCL, Parent-reported Internalizing symptomsPretreatment:G1: 9.50 (SD=7.33)G2: 8.76 (SD=5.69)Within group change at post-treatment assessment: G1: NRG2: NRBetween group change at post-treatment assessment: NRWithin group change at 3 Mos. assessment: G1: -2.00, d=0.29, p=NRG2: -1.33, d=0.21, p=NRBetween group change at 3 Mos. assessment: -0.67, p=NRWithin group change at 12 Mos. assessment:G1: -3.61, d=0.58, p=NR (RCI: 17.86% improved, 0% deteriorated)G2: -1.52, d=0.26, p=NR (RCI: 14.29% improved, 4.76% deteriorated)Between group change at 12 Mos. assessment: -2.09, ANOVA time\*treatment interaction p=NR; RCI difference p=NRInternalizing symptoms changed over time, F(2,94)=4.46, p=0.015 for both treatment conditions.CBCL, Parent-reported Externalizing symptomsPretreatment:G1: 12.39 (SD=7.49)G2: 10.05 (SD=8.73)Within group change at post-treatment assessment: G1: NRG2: NR |

Evidence Table 6. Benefits (KQ1 & 2) (continued)

|  |  |  |
| --- | --- | --- |
| Author, Year, Trial Name  | Prevention or Reduction in Physical Health Conditions or Symptoms  | Reduction in Risk-Taking Behaviors, Behavioral Problems, or Criminal Activities |
| Salloum, 201218 |  | Between group change at post-treatment assessment: NRWithin group change at 3 Mos. assessment: G1: 0.97, d=0.12, p=NRG2: 0.05, d=0.006, p=NRBetween group change at 3 Mos. assessment: 0.92, p=NRWithin group change at 12 Mos. assessment:G1: -2.78, d=0.35, p=NRG2: 0.57, d=0.06, p=NRBetween group change at 12 Mos. assessment: -2.21, ANOVA time\*treatment interaction using ITT analysis: F(2,108)=3.81, p=0.026 |
| Smith, 200719NA | NR | NR |
| Stein, 200320NA | NR | NR |
| Tol, 2008; 2010 21, 22 NA | NR | Parent-rated Children’s Aggression Scale for Parents (range: 33-132)PretreatmentG1: 42.18 (SD=9.09)G2: 44.63 (SD=12.08)Within group change at 1 week:G1: -1.44 (SD=4.72)G2: -1.16 (SD=4.23)Within group change at 6 Mos.:G1: -2.03 (SD=4.71)G2: -1.48 (SD=4.69)Between group difference at 1 week (95% CI): d=0.06 (-0.13, 0.25)Between group difference at 6 Mos. (95% CI): d=0.12 (-0.07, 0.31) |
| Tol, 201223 NA | NA | Conduct problems:Pretreatment:G1: 2.00 (SD=2.84)G2: 1.99 (SD=2.23)Within group change at post-treatment:G1: NRG2: NRBetween group change at post-treatment: NRLGCM estimate (SE): -0.132 (0.045); p<0.01 |

Evidence Table 6. Benefits (KQ1 & 2) (continued)

|  |  |  |
| --- | --- | --- |
| Author, Year, Trial Name  | Prevention or Reduction in Physical Health Conditions or Symptoms  | Reduction in Risk-Taking Behaviors, Behavioral Problems, or Criminal Activities |
| Zehnder, 201024NA | NR | CBCL-German version (range: NR), MeanPretreatment:G1: 53.4 (SD=9.3)G2: 50.6 (SD=9.1)Within group change at Time 1 assessment:G1: -3.4 (calculated)G2: -0.6 (calculated)Between group change at Time 1 assessment: -2.8 (calculated)Within group change at Time 2 assessment:G1: -2.6 (calculated)G2: -1.8 (calculated)Between group change at Time 2 assessment: -0.8 (calculated)Repeated measures ANOVA treatment\*time interaction: F=0.01, p=NS |

Note: No eligible study reported on decreased suicidality in the context of KQ1 or KQ2.

Abbreviations: CBCL = Child Behavior Checklist; CI = confidence interval; d = effect size; df = degrees of freedom; DPS = DISC Predictive Scales; ERASE-Stress – Enhancing Resilience among Students Experiencing Stress; ES-SL = ERASE Stress Sri Lanka; G = group; GHQ-12; General Health Questionnaire; ITT = Intent-to-treat; LGCM = latent growth curve modeling; Mos. = months; NA = not applicable; NR = not reported; NS = not significant; OTT = Overshadowing the Threat of Terrorism; RCI – Reliable Change Index; SD = standard deviation;; SE = standard error; SSET = Support for Students Exposed to Trauma; TARGET = Trauma Affect Regulation: Guide for Education and Therapy; TGCT = Trauma and Grief Component Therapy.